Pivot to Growth Strategy Progress: Teva is accelerating its Pivot to Growth strategy, focusing on transforming into a leading innovative biopharmaceutical company through late-stage innovative ...

Deliver on 2026 OJEMDA net product revenue guidance, with a focus on increasing persistency and driving new patient starts to support continued OJEMDA adoption as standard of care (SOC) in 2L ...

FRIENDSWOOD, Texas, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced certain ...

MBX plans to share the full 12-week dataset from Avail and one-year follow-up data at a medical conference in Q2 2026. An FDA End-of-Phase 2 meeting is planned for Q1 2026, as MBX continues to prepare ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva’s anti-IL-15 candidate TEV-‘408 TEV- ...

The HealthEx integration is available now for Claude Pro and Max users. Today, the service is anchored on giving consumers health insights based on their health history. In the future, consumers will ...

Krish S. Krishnan, Chairman and Chief Executive Officer, and Suma M. Krishnan, President of Research and Development, will highlight these updates and Krystal’s strategic vision in a presentation at ...

CARLSBAD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced select preliminary unaudited financial results for the fourth ...

In November 2025, KOMZIFTI was added to the National Comprehensive Cancer Network ® (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) as a Category 2A recommended treatment option ...

The company’s fourth quarter and full-year 2025 financial and operational results are preliminary and are subject to the completion of the company’s 2025 audit. Audited full-year 2025 and unaudited ...

• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued to demonstrate the powerful disease-modifying effects of BB-301, with ...

A new Consumer Analysis investigates the SleepZee Mouth Guard, examining the moldable anti-snoring device's published specifications, material composition claims, and company disclosure practices as ...